Avastin (Ovarian Cancer) Analysis and Forecasts to 2020


#28291

35pages

GlobalData

$ 2000

In Stock


GlobalDatas pharmaceuticals report, Avastin (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Avastin sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

 

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Avastin including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Avastin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2012-2020 for Avastin in the seven major markets

 

Reasons to buy

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 Ovarian Cancer 4
2.2 Ovarian Cancer Market 4
2.3 Epidemiology 4
2.4 Etiology 6
2.4.1 Age 6
2.4.2 Inherited Gene Mutations 6
2.4.3 A Previous Cancer Diagnosis 6
2.4.4 Early Menstruation or Late menopause 7
2.4.5 Family History of Ovarian Cancer 7
2.5 GlobalData Report Guidance 7


3 Ovarian Cancer: Market Characterization 8
3.1 Ovarian Cancer Market 8
3.2 Ovarian Cancer Market Forecasts and CAGR 8
3.3 Drivers for Ovarian Cancer Market 9
3.3.1 High Incidence 9
3.3.2 High Mortality Rate 10
3.3.3 Increased Use of Chemotherapy in Ovarian Cancer 11
3.3.4 Emergence of Targeted Drugs 11
3.3.5 Recurrence of Tumor 11
3.3.6 Low Initial Diagnosis Rate 11


4 Tumor-Node-Metastases (TNM) Classification of Ovarian Cancer 12


5 Avastin (bevacizumab) 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.3.1 First Line Trials 15
5.3.2 Second Line Trials 16
5.4 Approval History of Avastin 16
5.5 Factors Affecting Sales of Avastin 17
5.5.1 High Efficacy 17
5.5.2 Limited Treatment Options 17
5.5.3 Presence in Multiple Lines of Treatment 17
5.5.4 Wide Acceptance 17
5.6 Drug Evaluation 18
5.6.1 Drug Risk Benefit Score 18
5.6.2 Intensity of Competition 19
5.7 Sales Forecasts 19
5.7.1 Target Patient Pool of Avastin 19
5.7.2 Dosing 20
5.7.3 Market Penetration 20
5.7.4 Annual Cost of Therapy 21
5.7.5 Sales Forecasts of Avastin 22


6 Ovarian Cancer Market: Appendix 31
6.1 Market Definitions 31
6.2 List of Abberiviations 31
6.3 Research Methodology 31
6.3.1 Coverage 31
6.3.2 Secondary Research 32
6.3.3 Forecasting 32
6.3.4 Number of Patients Approved to take the Drug 32
6.3.5 Net Penetration of Drug 32
6.3.6 Net Annual Dosing 33
6.3.7 Annual Cost of Therapy 33
6.3.8 Primary Research 34
6.3.9 Expert Panels 34
6.4 Contact Us 34
6.5 Disclaimer 34
6.6 Sources 35


Table 1: Ovarian Cancer, Incidences and Mortality, 20082030 6
Table 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 8
Table 3: Detailed TNM Classification 13
Table 4: Approval History of Avastin 16
Table 5: Drug Risk Benefit Score of Avastin 18
Table 6: Avastin, Ovarian Cancer, Global, Annual Cost of Therapy ($), 2012 21
Table 7: Avastin, Ovarian Cancer, Global, Sales Forecasts ($m), 20122020 22
Table 8: Avastin, Ovarian Cancer, The US, Sales Forecasts ($m), 20122020 23
Table 9: Avastin, Ovarian Cancer, The UK, Sales Forecasts ($m), 20122020 24
Table 10: Avastin, Ovarian Cancer, France, Sales Forecasts ($m), 20122020 25
Table 11: Avastin, Ovarian Cancer, Germany, Sales Forecasts ($m), 20122020 26
Table 12: Avastin, Ovarian Cancer, Italy, Sales Forecasts ($m), 20122020 27
Table 13: Avastin, Ovarian Cancer, Spain, Sales Forecasts ($m), 20122020 28
Table 14: Avastin, Ovarian Cancer, Japan, Sales Forecasts ($m), 20132020 29


Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 5
Figure 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 8
Figure 3: Ovarian Cancer, Worldwide, Incidence (in million), 2008-2030 9
Figure 4: Oncology, Worldwide, Incidence (in million), 2008-2030 10
Figure 5: Ovarian Cancer, Worldwide, Mortality (in million), 2008-2030 10
Figure 6: Broad Classification of Ovarian Cancer 12
Figure 7: Classification of Ovarian Cancer 14
Figure 8: Drug Model Diagram of Avastin 20
Figure 9: Avastin, Ovarian Cancer, Global, Sales Forecasts ($m), 20122020 22
Figure 10: Avastin, Ovarian Cancer, The US, Sales Forecasts ($m), 20122020 23
Figure 11: Avastin, Ovarian Cancer, The UK, Sales Forecasts ($m), 20122020 24
Figure 12: Avastin, Ovarian Cancer, France, Sales Forecasts ($m), 20122020 25
Figure 13: Avastin, Ovarian Cancer, Germany, Sales Forecasts ($m), 20122020 26
Figure 14: Avastin, Ovarian Cancer, Italy, Sales Forecasts ($m), 20122020 27
Figure 15: Avastin, Ovarian Cancer, Spain, Sales Forecasts ($m), 20122020 28
Figure 16: Avastin, Ovarian Cancer, Japan, Sales Forecasts ($m), 20132020 29
Figure 17: Avastin, Ovarian Cancer, Global, Sales Distribution (%), 2018 30
Figure 18: Drug Model Diagram 33
Figure 19: Patients Approved for the Drug 33